Paris and Munich-based venture capitalist Kurma Partners has reached the first closing of its Biofund IV with EUR 140 million. Kurma's goal is to raise a total of EUR 250 million for its latest and largest venture capital fund to date by its final close in 2025.
Biofund IV is planning 16 to 20 new investments, the first three of which have already been made. As with its predecessor funds, the focus is on companies developing innovative therapeutics. The strategy remains balanced and risk-led, with investments in both start-ups and established companies, according to Kurma Partners.
A key element of Biofund IV is the close collaboration with academic scientists and the use of Kurma's networks of experienced industry experts to create synergies that promote the growth of the portfolio companies. Biofund IV has already been invested in the EUR 63 million Series A financing round of the Martinsried-based start-up SciRhom in July 2024.